By participating in the project, the company, located in Tokyo, hopes to improve its cloud-based data management services while winning over new customers.
Chipscreen is developing a small molecule inhibitor of key serine-threonine kinases involved in tumor angiogenesis, cell mitosis, and microenvironment inflammation.
In PLOS this week: missense variant linked to hereditary leukodystrophy in dogs, genetic variants associated with drug-induced interstitial lung disease, and more.
The company was originally founded as a spinoff from Korean genomic services provider Macrogen to offer direct-to-consumer genomic rare disease screening tests.
Data from more than 11,800 women with breast cancer suggested unselected BRCA1, BRCA2, and PALB2 testing is cost-effective for UK and US payors and societies.
The company claims that certain Illumina sequencers infringe its US Patent No. 9,944,984, "Methods and Compositions for Efficient Base Calling in Sequencing Reactions."
